|
|
|
| Effect of Adjuvant Therapy with Compound Hongdoushan Capsules on Peripheral Blood T Lymphocyte Subsets and Vascular Endothelial Growth Factors in Patients with Ovarian Cancer Treated with Chemotherapy |
| YU Jing, YE Lin-yan |
| Department of Pharmacy, Mianyang Central Hospital,Mianyang, Sichuan, 621000 |
|
|
|
|
Abstract 【Objective】To investigate the effect of adjuvant therapy with Compound Hongdoushan Capsules on peripheral blood T lymphocyte subsets and vascular endothelial growth factors (VEGF) in patients with ovarian cancer treated by chemotherapy after operation. 【Methods】 A total of 88 cases of patients with ovarian cancer treated in our hospital during March 2012 to April 2016 were selected and randomly divided into the control group and the observation group by the random number table method, with 44 cases in each group. Both groups were treated with radical resection of ovarian cancer combined with postoperative chemotherapy, and patients in the observation group were additionally treated with Compound Hongdoushan Capsules. The therapeutic effects were compared between the two groups, and changes of levels of T lymphocyte subsets such as CD3+, CD4+, CD8+, and CD4+/CD8+ in peripheral blood were detected before and after treatment. The changes of VEGF, interleukin -6 (IL-6), interleukin -8 (IL-8), and tumor necrosis factor α (TNF-α) levels were determined before and after treatment, and the incidence of side effects in the two groups was statistically analyzed. 【Results】 The total remission rate of the observation group was higher than that of the control group ( P < 0.05). Before treatment, there was no significant difference in the levels of CD3+, CD4+, CD8+, CD4+/CD8+, IL-6, IL-8, TNF-α, and VEGF between the two groups ( P > 0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ in the observation group were higher than those in the control group, and the levels of IL-6, IL-8, TNF-α and VEGF in the observation group were lower than those in the control group ( P < 0.05). The incidence rates of grade Ⅰ~Ⅱ gastrointestinal reactions, hematuria, and WBC count decline in the observation group were lower than those in the control group ( P < 0.05). 【Conclusion】The adjuvant therapy with Compound Hongdoushan Capsules has synergistic effects in the chemotherapy of ovarian cancer. It can optimize the effects of chemotherapy, improve the immune function and reduce the side effects.
|
|
Received: 21 September 2017
|
|
|
|
|
|
[1] 黄婧,周月华.紫杉醇联合顺铂或卡铂治疗晚期卵巢癌的疗效观察[J].医学临床研究,2013,30(1):47-49.
[2] 彭利红,高翠红.卵巢癌患者的免疫功能探讨[J].标记免疫分析与临床,2016,23(2):174-176.
[3] 张晓炜. 复方红豆杉胶囊联合 TP方案治疗中晚期非小细胞肺癌的疗效观察[J].陕西中医,2015,36(7):833-835.
[4] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90.
[5] 世界卫生组织.抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992, 3:254.
[6] 章迅,安青,章永红,等.复方红豆杉方加减联合化疗用于晚期乳腺癌的疗效观察[J].国际中医中药杂志,2013,35(8):719-720. [7] 乔志伟,王纯雁,王蕾,等.新辅助化疗联合肿瘤细胞减灭术中热灌注治疗晚期卵巢癌疗效观察[J].湖南师范大学学报(医学版),2015,12(1):83-85.
[8] 杨远游,程海民,穆晓峰,等.复方红豆杉胶囊治疗高龄肺癌1例[J].第三军医大学学报,2014,36(1):54.
[9] 李佳俐,易建莉,胡彦,等.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效分析[J].医学临床研究,2013,30(5):998-999.
[10] 胡娟,赵长新,李永明,等.血清糖链抗原(125、19-9)、血管内皮生长因子 C水平与卵巢癌淋巴结转移的关系[J].中国基层医药,2016,23(4):485-488,489.
[11] 厉碧荣,李劼,王静云,等.紫花牡荆素对卵巢癌OVCAR-3细胞系肿瘤球形成的影响[J].湖南师范大学学报(医学版),2014,11(2):43-45.
[12] 李娜,高家志,朱颖,等.新辅助化疗联合洛铂术中腹腔灌注在卵巢癌中的效果评价及其机制研究[J].中国医院药学杂志,2016,36(7):582-584,602. |
|
|
|
2018, Vol. 35 
